Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Articles by Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLPublished: January 8th 2021 | Updated:
Allogeneic Transplantation for CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment: Addressing Unmet NeedsPublished: January 8th 2021 | Updated:
Selecting Frontline Therapy to Treat CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment With Fixed-Duration RegimensPublished: January 8th 2021 | Updated:
Minimal Residual Disease in CLLPublished: January 8th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5